Browse by Category


A Biosimilar OK’d for Breast Cancer Treatment

The FDA approved Ogivri (trastuzumab-dkst), a biosimilar drug to Herceptin (trastuzumab), to treat patients with breast or metastatic stomach cancer. Ogivri is the first biosimilar approved in the U.S. for the treatment of breast or stomach cancer. Common side effects associated with Ogivri for the treatment of breast cancer include…